Tumor-targeting ligands conjugated to nanoparticles can selectively bind to over-expressed cancer cell surface receptors, improve specific cancer cell binding, and result in increased cancer cell-specific uptake of therapeutics into tumor cells via receptor-mediated endocytosis [65,66,67,68]. This evidence concerns the gene CD177 and neoplasm.